Bleomycin-induced pulmonary toxitity usually occurs in the elderly patients (graeatee than 70 years old), patients with a cumulative dose above 400 units, previous chest radiotherapy, oxygen therapy, and reanal failure. However, there are some reports of severe pneumonitis in that developed after dministering low bleomycin doses (less than 100 units). In sever bleomycin-induced pneumonitis in non-Hodgkin's lymphoma patients, the response to corticosteroid is poor and the mortality rate is very high, approximately 83%. Therefore, clinicians should have a low threshold for investigating and treating bleomycin-induced pneumonitis. Here, we report a case of severe bleomycin-induced pneumonitis as a complication of a non-Hodgkin's lymphoma treatment.